Hodgkin's lymphoma

Cover Page
  • Authors: Demina E.A.1, Tumyan G.S.2,3, Moiseeva T.N.4, Mikhailova N.B.5, Myakova N.V.6, Rumyantsev A.G.6, Maschan A.A.6, Kaplanov K.D.7,8, Shmakov R.G.9, Falaleeva N.A.10, Ptushkin V.V.11, Osmanov E.A.12,13, Poddubnaya I.V.14, Baikov V.V.15, Kovrigina A.M.16,17, Konovalov D.M.6, Trofimova O.P.18,14, Sotnikov V.M.19, Ilin N.V.20, Vinogradova Y.N.20, Nechesnyuk A.V.21, Parkhomenko R.A.19, Stefanov D.N.21, Nevolsky A.A.22, Ivanov S.A.22, Khaylova Z.V.10
  • Affiliations:
    1. FSBI National Medical and Surgical Center named after N.I. Pirogova »Ministry of Health of Russia
    2. FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia
    3. FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
    4. FSBI National Medical Research Center for Hematology
    5. FSBEI of HE “First St. Petersburg State Medical University named after Acad. I.P. Pavlova »Ministry of Health of Russia
    6. FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev »Ministry of Health of Russia
    7. GBUZ "Volgograd Regional Clinical Oncology Center"
    8. FSBEI HE "Volgograd State Medical University" of the Ministry of Health of Russia
    9. FSBI “National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Acad. IN AND. Kulakova »Ministry of Health of Russia
    10. Medical Radiological Scientific Center. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia
    11. City Clinical Hospital named after S.P. Botkin
    12. FSBI “National Medical Research Center of Oncology named after N.N. Blokhin »Ministry of Health of Russia
    13. Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after I.M. Sechenov» Ministry of Health of Russia
    14. FSBEI DPO "Russian Medical Academy of Continuing Professional Education" of the Ministry of Health of Russia
    15. FSBEI of HE “First St. Petersburg State Medical University named after Acad. I.P. Pavlov» Ministry of Health of Russia
    16. FSBI FNCC FMBA of Russia
    17. Federal State Budgetary Institution "National Medical Research Center of Hematology" of the Ministry of Health of Russia
    18. FSBI "National Medical Research Center. N.N. Blokhin »Ministry of Health of Russia
    19. FSBI “Russian Scientific Center of X-ray Radiology” of the Ministry of Health of Russia
    20. FSBI Russian Scientific Center of Radiology and Surgical Technologies. Acad. A.M. Granov» Ministry of Health of Russia
    21. FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia
    22. Medical Radiological Scientific Center. them. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia
  • Issue: Vol 22, No 2 (2020)
  • Pages: 6-33
  • Section: Guidelines
  • URL: https://journals.rcsi.science/1815-1434/article/view/34876
  • DOI: https://doi.org/10.26442/18151434.2020.2.200132
  • ID: 34876

Cite item

Full Text

Abstract

Clinical recommendations.

About the authors

E. A. Demina

FSBI National Medical and Surgical Center named after N.I. Pirogova »Ministry of Health of Russia

Author for correspondence.
Email: or@hpmp.ru

Dr. med. sciences, prof., prof. cafe Hematology and Cell Therapy Institute for Advanced Medical Studies, Member of the Board of the Russian Society of Oncohematologists

Russian Federation, Moscow

G. S. Tumyan

FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia; FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, prof., prof. cafe oncology and palliative medicine, Vedas. scientific al. Hemoblastosis chemotherapy department, member of the board of the Russian Society of Oncohematologists

Russian Federation, Moscow

T. N. Moiseeva

FSBI National Medical Research Center for Hematology

Email: or@hpmp.ru

Cand. med. sciences, head. Advisory hematology department with a day hospital for intensive high-dose chemotherapy, member of the National Hematology Society

Russian Federation, Moscow

N. B. Mikhailova

FSBEI of HE “First St. Petersburg State Medical University named after Acad. I.P. Pavlova »Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, hands. Dep. clinical oncology (chemotherapy) Research Institute of Pediatric Oncology, Hematology and Transplantology. R.M. Gorbachev, member of the Russian Society of Oncohematologists

Russian Federation, St. Petersburg

N. V. Myakova

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev »Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, prof., deputy chapters. medical doctor, head Department of Oncohematology, member of the National Society of Pediatric Hematologists and Oncologists

Russian Federation, Moscow

A. G. Rumyantsev

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev »Ministry of Health of Russia

Email: or@hpmp.ru

Acad. RAS, Dr. med. sciences, prof., gen. Dir., President of the National Society of Pediatric Hematologists and Oncologists

Russian Federation, Moscow

A. A. Maschan

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev »Ministry of Health of Russia

Email: or@hpmp.ru

Corr. RAS, Dr. med. sciences, prof., deputy gene. Dir., Member of the Board of the National Society of Pediatric Hematologists and Oncologists

Russian Federation, Moscow

K. D. Kaplanov

GBUZ "Volgograd Regional Clinical Oncology Center"; FSBEI HE "Volgograd State Medical University" of the Ministry of Health of Russia

Email: or@hpmp.ru

Cand. med. sciences, head. Department of Hematology, Assistant oncology with a course of oncology and hematology FUV, member of the Russian Society of Oncohematologists and the National Hematology Society

Russian Federation, Volgograd

R. G. Shmakov

FSBI “National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Acad. IN AND. Kulakova »Ministry of Health of Russia

Email: or@hpmp.ru

prof. RAS, Dr. med. sciences, dir. Institute of Obstetrics, Member of the Board of the Russian Society of Obstetricians and Gynecologists

Russian Federation, Moscow

N. A. Falaleeva

Medical Radiological Scientific Center. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, head. Department of Anticancer Drug Treatment, Member of the Association of Oncologists of Russia and the Russian Association of Therapeutic Radiation Oncologists

Russian Federation, Obninsk

V. V. Ptushkin

City Clinical Hospital named after S.P. Botkin

Email: or@hpmp.ru

Dr. med. sciences, prof., deputy chapters. hematology doctor, chapters. Freelance specialist-hematologist of the Moscow Department of Health, member of the National Hematology Society and the Russian Society of Oncohematologists

Russian Federation, Moscow

E. A. Osmanov

FSBI “National Medical Research Center of Oncology named after N.N. Blokhin »Ministry of Health of Russia; Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after I.M. Sechenov» Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, prof., head. Dep. hematology and bone marrow transplantation, prof. cafe oncology, member of the board of the Russian Society of Oncohematologists

Russian Federation, Moscow

I. V. Poddubnaya

FSBEI DPO "Russian Medical Academy of Continuing Professional Education" of the Ministry of Health of Russia

Email: or@hpmp.ru

Acad. Russian Academy of Sciences, honored. Education Worker of the Russian Federation, Dr. med. sciences, prof., head. cafe oncology and palliative medicine, vice-rector for medical work and international cooperation, chairman of the Russian Society of Oncohematologists

Russian Federation, Moscow

V. V. Baikov

FSBEI of HE “First St. Petersburg State Medical University named after Acad. I.P. Pavlov» Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, prof. cafe pathological anatomy, head. lab. Pathomorphology Research Institute of Pediatric Oncology, Hematology and Transplantology. R.M. Gorbachev, Member of the Presidium of the Russian Society of Pathologists, Member of the Board of the Russian Society of Oncohematologists

Russian Federation, Moscow

A. M. Kovrigina

FSBI FNCC FMBA of Russia; Federal State Budgetary Institution "National Medical Research Center of Hematology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Dr. biol. sciences, prof. cafe pathological anatomy, cytology and molecular pathology of the Academy of postgraduate education, head. pathologist, member of the Presidium of the Russian Society of Pathologists, member of the Board of the Russian Society of Oncohematologists

Russian Federation, Moscow

D. M. Konovalov

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev »Ministry of Health of Russia

Email: or@hpmp.ru

Cand. med. sciences, head. pathological department

Russian Federation, Moscow

O. P. Trofimova

FSBI "National Medical Research Center. N.N. Blokhin »Ministry of Health of Russia; FSBEI DPO "Russian Medical Academy of Continuing Professional Education" of the Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. Sciences, Ved. scientific al. radiological department, Assoc. cafe oncology, member of the Russian Association of Therapeutic Radiation Oncologists

Russian Federation, Moscow

V. M. Sotnikov

FSBI “Russian Scientific Center of X-ray Radiology” of the Ministry of Health of Russia

Email: or@hpmp.ru

Dr. honey sciences, hands. lab. radiation therapy

Russian Federation, Moscow

N. V. Ilin

FSBI Russian Scientific Center of Radiology and Surgical Technologies. Acad. A.M. Granov» Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, prof., prof. cafe radiology, surgery and oncology, chapters. scientific al. Dep. radiation and combined treatments

Russian Federation, Moscow

Yu. N. Vinogradova

FSBI Russian Scientific Center of Radiology and Surgical Technologies. Acad. A.M. Granov» Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, hands. Dep. radiation and combined treatment methods, chapters. scientific al. Dep. radiation and combined treatments

Russian Federation, Moscow

A. V. Nechesnyuk

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, head. Department of Radiation Therapy, Member of the National Society of Pediatric Hematologists and Oncologists

Russian Federation, Moscow

R. A. Parkhomenko

FSBI “Russian Scientific Center of X-ray Radiology” of the Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. Sciences, Art. scientific al. lab. complex methods of treating cancer in children

Russian Federation, Moscow

D. N. Stefanov

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia

Email: or@hpmp.ru

Researcher, Scientific and Organizational Department, Member of the Russian Society of Oncohematologists

Russian Federation, Москва

A. A. Nevolsky

Medical Radiological Scientific Center. them. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Dr. med. sciences, deputy Dir. on medical work

Russian Federation, Obninsk

S. A. Ivanov

Medical Radiological Scientific Center. them. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

prof. RAS, Dr. med. sciences, dir.

Russian Federation, Obninsk

Zh. V. Khaylova

Medical Radiological Scientific Center. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Cand. med. sciences, deputy dir. on organizational and methodological work

Russian Federation, Obninsk

References

  1. Демина Е.А. и др. Общие принципы диагностики лимфом. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 9–27. [Demina E.A. et al. General principles for the diagnosis of lymphomas. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Pod red. I.V. Poddubnoi, V.G. Savchenko 2018; s. 9–27. (in Russian).]
  2. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii’ Minzdrava Rossii, 201 (in Russian).]
  3. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Ed. Swerdlow SH, Campo E, Harris NL et al. Lyon, France: International Agency for Research in Cancer (IARC), 2017.
  4. Демина Е.А. и др. Лимфома Ходжкина. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 28–43. [Demina E.A. et al. Hodgkin’s lymphoma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Pod red. I.V. Poddubnoi, V.G. Savchenko. 2018; c. 28–43 (in Russian).]
  5. Kennedy-Nasser AA, Hanley P, Bollard CM. Hodgkin disease and the role of the immune system. Pediatr Hematol Oncol NIH Public Access 2011; 28 (3): 176–86.
  6. Good RA. Relations between immunity and malignancy. Proceedings of the National Academy of Sciences of the United States of America. 1972; 69 (4): 1026–32.
  7. Шмаков Р.Г., Демина Е.А. Лимфомы и беременность. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 143–50. [Shmakov R.G., Demina E.A. Lymphomas and pregnancy. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Pod red. I.V. Poddubnoi, V.G.Savchenko. 2018; s. 143–50 (in Russian).]
  8. Kanoun S, Rossi C, Casasnovas O. [18F]FDG-PET/CT in hodgkin lymphoma: Current usefulness and perspectives. Cancers 2018.
  9. Yokoyama K. Thrombosis in lymphoma patients and in myeloma patients. Keio J Med. Keio University School of Medicine 2015; 64 (3): 37–43.
  10. Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. СПб: КОСТА, 2006. [Krivolapov Iu.A., Leenman E.E. Morphological diagnosis of lymphomas.. Saint Petersburg: KOSTA, 2006 (in Russian).]
  11. Adams HJA, Nievelstein RAJ, Kwee TC. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev Churchill Livingstone 2015; 29 (6): 417–25.
  12. Моисеева Т.Н., Аль-Ради Л.С., Дорохина Е.И. Протокол диагностики и лечения классической лимфомы Ходжкина. Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. НМИЦ Гематологии. 2018; c. 39–56. [Moiseeva T.N., Al’-Radi L.S., Dorokhina E.I. Protocol for the diagnosis and treatment of classical Hodgkin lymphoma. Diagnostic algorithms and protocols for the treatment of diseases of the blood system. Pod red. V.G. Savchenko. NMITs Gematologii. 2018; c. 39–56 (in Russian).]
  13. Engert A et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007; 200: 3495–502.
  14. Meyer RM et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012; 366 (5): 399–408.
  15. Allen PB, Gordon LI. Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors. Clinical Medicine Insights: Oncology. SAGE Publications Ltd, 2017; 11.
  16. Skoetz N et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database of Systematic Reviews, 2017.
  17. Von Tresckow B et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol 2012; 30 (9): 907–13.
  18. Hoppe BS et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012; 84 (2): 449–55.
  19. Hoppe BS et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol 2017; 28 (9): 2179–84.
  20. Tseng YD et al. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys 2017; 99 (4): 825–42.
  21. Engert A et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non- inferiority trial. Lancet 2012; 379 (9828): 1791–9.
  22. Демина Е.А. и др. Оптимизация терапии первой линии у пациентов с распространенными стадиями лимфомы Ходжкина: эффективность и токсичность интенсивной схемы EACOPP-14 (опыт ФГБУ «НМИЦ онкологии им. Н.Н. Блохина Минздрава России). Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2017; 10 (4): 443–52. [Demina E.A. i dr. Optimizatsiia terapii pervoi linii u patsientov s rasprostranennymi stadiiami limfomy Khodzhkina: effektivnost’ i toksichnost’ intensivnoi skhemy EACOPP-14 (opyt FGBU «NMITs onkologii im. N.N. Blokhina Minzdrava Rossii). Klinicheskaia onkogematologiia. Fundamental’nye issledovaniia i klinicheskaia praktika. 2017; 10 (4): 443–52 (in Russian).]
  23. Sieber M et al. 14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: Results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003; 21 (9): 1734–9.
  24. Gallamini A et al. Consolidation radiotherapy could be omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD. Final analysis of the randomized HD0607 trial. Hematol Oncol Wiley 2019; 37: 147–8.
  25. Barrington SF et al. PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood Am Soc Hematol 2016; 127 (12): 1531–8.
  26. Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 8 (Suppl. 2): S63–6.
  27. Engel C et al. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group (GHSG). Ann Oncol Off J Eur Soc Med Oncol 2000; 11 (9): 1105–14.
  28. Lymphoma H. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) NCCN.org NCCN Guidelines for Patients® available at www.nccn.org/patients. 2019.
  29. Yahalom J et al. Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 2015; 92 (1): 11–31.
  30. Connors JM et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018; 378 (4): 331–44.
  31. Mauz-Körholz C et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: The GPOH-HD-2002 study. J Clin Oncol 2010; 28 (23): 3680–6.
  32. Dörffel W et al. Treatment of children and adolescents with hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD95. J Clin Oncol 2013; 31 (12): 1562–8.
  33. Hudson MM, Constine LS. Refining the role of radiation therapy in pediatric hodgkin lymphoma. Am Soc Clin Oncol Educ Book. From the Department of Oncology, Division of Cancer Survivorship, St. Jude’s Children’s Research Hospital, Memphis, TN; Departments of Radiation Oncology and Pediatrics, Philip Rubin Center for Cancer Survivorship, James P. Wilmot Cancer Center at Univers: American Society of Clinical Oncology, 2012; p. 616–20.
  34. International Commission on Radiation Units and Measurments. Prescribing, Recording, and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). 1999.
  35. Румянцев А.Г., Самочатова Е.В. Практическое руководство по детским болезням. Гематология/онкология детского возраста. М.: Медпрактика-М, 2004. [Rumiantsev A.G., Samochatova E.V. A practical guide to childhood illnesses. Pediatric Hematology /Oncology. Moscow: Medpraktika-M, 2004 (in Russian).]
  36. Borchmann S, Engert A, Böll B. Hodgkin lymphoma in elderly patients. Curr Opin Oncol 2018; 30 (5): 308–16.
  37. Thyss A et al. Hodgkin’s lymphoma in older patients: An orphan disease? Mediterr J Hematol Infect Dis 2014; 6 (1): 1–10.
  38. Капланов К.Д. и др. Программа IVDG – возможный выбор первой линии терапии лимфомы Ходжкина у пациентов пожилого возраста с сопутствующими сердечно-сосудистыми и легочными заболеваниями. Клин. онкогематология. 2017; 10 (3): 358–65.[Kaplanov K.D. et al. Programma IVDG – vozmozhnyi vybor pervoi linii terapii limfomy Khodzhkina u patsientov pozhilogo vozrasta s soputstvuiushchimi serdechno-sosudistymi i legochnymi zabolevaniiami. Klin. onkogematologiia. 2017; 10 (3): 358–65 (in Russian).]
  39. Fedele R et al. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res 2015; 2015: 968212.
  40. Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol 2017; 8 (10): 293–302.
  41. Mohty M et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: A position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014; 20: 295–308.
  42. Moskowitz AJ et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116 (23): 4934–7.
  43. Moskowitz CH et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018; 132 (25): 2639–42.
  44. Chen R et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128 (12): 1562–6.
  45. Younes A et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17 (9): 1283–94.
  46. Chen R et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. Am Soc Hematol 2019; 134 (14): 1144–53.
  47. Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant 2016: 51 (4): 521–8.
  48. Peggs KS. Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv Am Soc Hematol 2018; 2 (7): 817–20.
  49. Wirth A et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005; 104 (6): 1221–9.
  50. Nogová L et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol Off J Eur Soc Med Oncol 2005; 16 (10): 1683–7.
  51. Eichenauer DA et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocytepredominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood 2011; 118 (16): 4363–5.
  52. Appel BE et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant hodgkin lymphoma: A report from the children’s oncology group. J Clin Oncol 2016; 34 (20): 2372–9.
  53. Mauz-Körholz C et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110 (1): 179–85.
  54. Cencini E, Fabbri A, Bocchia M. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol 2017; 176 (5): 831–3.
  55. Shankar A et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma – An Anglo-French collaborative report. Eur J Cancer 2012; 48 (11): 1700–6.
  56. Fanale MA et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood 2017; 130: 472–7.
  57. Advani RH, Hoppe RT. How i treat nodular lymphocyte predominant Hodgkin lymphoma. Blood 2013; 122 (26): 4182–8.
  58. Eichenauer DA et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: An analysis from the German Hodgkin Study Group. Blood 2018; 132 (14): 1519–25.
  59. Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: A unique disease deserving unique management. Hematology 2017; 2017 (1): 324–8.
  60. Bachanova V, Connors JM. Hodgkin lymphoma in pregnancy. Curr Hematol Malig Rep 2013; 8 (3): 211–7.
  61. Avilés A, Neri N, Nambo MJ. Hematological malignancies and pregnancy: Treat or no treat during first trimester. Int J Cancer 2012; 131 (11): 2678–83.
  62. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
  63. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 251–3.[Bariakh E.A., Miakova N.V., Poddubnaia I.V. Prevention and treatment of tumor lysis syndrome. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Pod red. I.V. Poddubnoi, V.G. Savchenko. 2018; s. 251–3 (in Russian).]
  64. Aapro M и др. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.[Aapro M et al. Clinical recommendations for the treatment of anemia in patients with malignant neoplasms. Moscow: Assotsiatsiia onkologov Rossii, 2014 (in Russian).]
  65. Орлова Р.В. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 494–501.[Orlova R.V. et al. Practical recommendations for the treatment of anemia in malignant neoplasms. Practical recommendations of the Russian Society of Clinical Oncology. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; s. 494–501 (in Russian).]
  66. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11.[Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol’nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; s. 502–11 (in Russian).]
  67. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 289–311.[Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Treatment and prevention of infectious complications in patients with lymphoproliferative diseases. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Pod red. I.V. Poddubnoi, V.G. Savchenko. 2018; s. 289–311 (in Russian).]
  68. Srivastava S, Wood P. Secondary antibody deficiency-causes and approach to diagnosis. Clin Med J R Coll Physicians 2016; 16: 571–6.
  69. Traila A et al. Fertility preservation in hodgkin’s lymphoma patients that undergo targeted molecular therapies: An important step forward from the chemotherapy era. Cancer Manag Res 2018; 10: 1517–26.
  70. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7 (6): 535–43.
  71. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016.[Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).]
  72. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 278–88.[Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol’nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V. Poddubnoi, V.G. Savchenko. 2018; s. 278–88 (in Russian).]
  73. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90: 5 (Suppl. 1): S88-94.
  74. Hancock BW et al. ChIVPP alternating with PABIOE is superior to PABIOE alone in the initial treatment of advanced hodgkin’s disease: Results of a british national lymphoma investigation/central lymphoma group randomized controlled trial. Br J Cancer 2001; 84 (10): 1293–300.
  75. Pavlovsky S et al. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin’s disease. J Clin Oncol 1997; 15: 7: 2652–8.
  76. Sieber M et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol Off J Eur Soc Med Oncol 2004; 15 (2): 276–82.
  77. Zallio F et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol 2016; 172 (6): 879–8.
  78. Levis A et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin’s disease patients. Haematologica 1996; 81 (5): 450–6.
  79. Santoro A et al. Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007; 92, (1): 35–41.
  80. Jeon SY et al. The effect of the dexamethasone, cytarabine, and cisplatin (Dhap) regimen on stem cell mobilization and transplant outcomes of patients with non-hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation. Korean J Intern Med 2018; 33 (6): 1169–81.
  81. Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Stem Cell Res 2015; 9 (1): 10–4.
  82. Hu B et al. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (Ifosfamide, carboplatin, etoposide) in relapsed or refractory classical hodgkin lymphoma. Leuk Lymphoma 2018; 59 (4): 863–70.
  83. Gutierrez A et al. Gemcitabine and oxaliplatinum: An effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther 2014; 7: 2093–100.
  84. Schellong G et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: Results from a multicenter study of the pediatric DAL/GPOH-HD Study Group. J Clin Oncol 2005; 23 (25): 6181–9.
  85. Long GV et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018; 29 (11): 2208–13.
  86. Singer S et al. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 2019; 25 (6): 1107–15.
  87. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
  88. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50 (8): 1257–60.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 6.3.1. Lymphatic sites

Download (524KB)
Indexing metadata
3. Fig. 6.3.2. The areas of lymphatic basin to determine prognostic groups according to the GHSG system.

Download (301KB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies